Trial Profile
A Multi-Center, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study to Determine the Safety of PEP005 [ingenol mebutate] 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 & 2 or Day 1 & 8 Applications to Actinic Keratoses
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2015
Price :
$35
*
At a glance
- Drugs Ingenol mebutate (Primary)
- Indications Actinic keratosis; Skin cancer
- Focus Adverse reactions
- Sponsors Peplin
- 19 Apr 2008 New trial record.